The effects of atorvastatin therapy on rheological characteristics of erythrocyte membrane, serum lipid profile and oxidative status in patients with dyslipidemia

Journal of Membrane Biology

Volumn 245, Issue 11, 2012, Pages 697-705

  Uydu, Hüseyin Avni ^a   Yildirmiş, Sermet ^b   Örem, Cihan ^b   Calapoglu, Mustafa ^c   Alver, Ahmet ^b   Kural, Birgü ^b   Örem, Asim ^b  

^a RECEP TAYYIP ERDOGAN UNIVERSITY   (Turkey)

^b KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^c SULEYMAN DEMIREL UNIVERSITY   (Turkey)

Author keywords

Atorvastatin; Dyslipidemia; Erythrocyte lipid; Na+ K + ATPase; Osmotic fragility; TAS; TBARS

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ATORVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; ERYTHROCYTE MEMBRANE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIPID PEROXIDATION; MALE; OSMOTIC FRAGILITY; OXIDATIVE STRESS; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; DYSLIPIDEMIAS; ERYTHROCYTE MEMBRANE; FEMALE; HEPTANOIC ACIDS; HUMANS; LIPID PEROXIDATION; LIPIDS; MALE; MEMBRANE FLUIDITY; MIDDLE AGED; OXIDATION-REDUCTION; PYRROLES; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 84871316742     PISSN: 00222631     EISSN: 14321424     Source Type: Journal    
DOI: 10.1007/s00232-012-9441-7     Document Type: Article

References (40)

1. Arsenault BJ, Barter P, DeMicco DA, Bao W, Preston GM, LaRosa JC, Grundy SM, Deedwania P, Greten H, Wenger NK, Shepherd J, Waters DD, Kastelein JJ, TNT Study Investigators (2011) Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. J Am Coll Cardiol 57(1):63-69
2. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP (2011) Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc Med J 5:24-34
3. Austin MA, McKnight B, Edwards KL, Bradley CM, McNeely MJ, Psaty BM, Brunzell JD, Motulsky AG (2000) Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study. Circulation 101(24):2777-2782
4. Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ (2010) Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER database. J Lipid Res 51(6):1546-1553
5. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A (2000) Non-lipidrelated effects of statins. Ann Med 32(3):164-176
6. Bełtowski J, Wójcicka G, Jamroz-Wiśniewska A (2009) Adverse effects of statins: mechanisms and consequences. Curr Drug Saf 4(3):209-228
7. Calişkan S, Calişkan M, Kuralay F, Onvural B (2000) Effect of simvastatin therapy on blood and tissue ATP levels and erythrocyte membrane lipid composition. Res Exp Med (Berl) 199(4):189-194
8. +)-ATPase in human erythrocytes. Biochim Biophys Acta 691:71-82
9. Chopra V, Flanders SA (2009) Does statin use improve pneumonia outcomes+ Chest 136(5):1381-1388
10. De Freitas MV, de Oliveira MR, dos Santos DF, de Cássia Mascarenhas Netto R, Fenelon SB, Penha-Silva N (2010) Influence of the use of statin on the stability of erythrocyte membranes in multiple sclerosis. J Membr Biol 233(1-3): 127-134
11. De Queiroz Mello AP, da Silva IT, Oliveira AS, Nunes VS, Abdalla DS, Gidlund M, Damasceno NR (2010) Electronegative lowdensity lipoprotein is associated with dense low-density lipoprotein in subjects with different levels of cardiovascular risk. Lipids 45(7):619-625
12. Dodge JT, Mitchell C, Hanahan DJ (1963) The preparation and chemical characteristics of hemoglobin-free ghosts of human erythrocytes. Arch Biochem Biophys 100:119-130
13. Dwight JF, Mendes Ribeiro AC, Hendry BM (1996) Effects of HMGCoA reductase inhibition on erythrocyte membrane cholesterol and acyl chain composition. Clin Chim Acta 256(1):53-63
14. Findlay JB, Evans WH (1987) Biological membranes. Oxford University Press, New York, pp 119-121
15. Garnier M, Perret G, Pilardeau P, Vaysse J, Rolland Y, Uzzan B, Vassy R (1988) Effect of diosmin upon red blood cell deformability and osmotic fragility. Relationship with lipid content. Methods Find Exp Clin Pharmacol 10(4):259-262
16. Jones PH, Goldberg AC, Knapp HR, Kelly MT, Setze CM, Stolzenbach JC, Sleep DJ (2010) Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. Am Heart J 160(4):7 59-766
17. Kanakaraj P, Singh M (1989) Influence of hypercholesterolemia on morphological and rheological characteristics of erythrocytes. Atherosclerosis 76(2-3):209-218
18. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK (2010) Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 55(12):1209-1216
19. Koter M, Broncel M, Chojnowska-Jezierska J, Klikczynska K, Franiak I (2002) The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia. Eur J Clin Pharmacol 58(8):501-506
20. Koter M, Franiak I, Strychalska K, Broncel M, Chojnowska-Jezierska J (2004) Damage to the structure of erythrocyte plasma membranes in patients with type-2 hypercholesterolemia. Int J Biochem Cell Biol 36(2):205-215
21. Levy Y, Leibowitz R, Aviram M, Brook JG, Cogan U (1992) Reduction of plasma cholesterol by lovastatin normalizes erythrocyte membrane fluidity in patients with severe hypercholesterolaemia. Br J Clin Pharmacol 34(5):427-430
22. Lijnen P, Echevaría-Vázquez D, Petrov V (1996) Influence of cholesterol-lowering on plasma membrane lipids and function. Methods Find Exp Clin Pharmacol 18(2):123-136
23. Martinez M, Vaya A, Marti R, Gil L, Lluch I, Carmena R, Aznar J (1996) Effect of HMG-CoA reductase inhibitors on red blood cell membrane lipids and haemorheological parameters, in patients affected by familial hypercholesterolemia. Haemostasis 26(Suppl 4):171-176
24. Mason RP, Walter MF, Day CA, Jacob RF (2006) Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. J Biol Chem 281(14):9337-9345
25. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A (1993) A novel method for measuring antioxidant capacity and its application to monitoring antioxidant status in premature neonates. Clin Sci 34:407-412
26. Orem C, Orem A, Uydu HA, Celik S, Erdöl C, Kural BV (2002) The effects of lipid-lowering therapy on low-density lipoprotein autoantibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status. Coron Artery Dis 13(1):65-71
27. Ott P, Binggeli Y, Brodbeck U (1982) Rapid and sensitive assay for determination of cholesterol in membrane lipid extracts. BBA Biomembr 685:211-213
28. Özdemirler G, Küçük S, Orhan Y, Aykaç-Toker G, Uysal M (2001) Lipid and protein oxidation in erythrocyte membranes of hypercholesterolemic subjects. Clin Biochem 34(4):335-339
29. Parpart AK, Lorenz PB, Parpart ER, Gregg JR, Chase AM (1947) The osmotic resistance (fragility) of human red cells. J Clin Invest 26(4):636-640
30. Rabini RA, Polenta M, Staffolani R, Tocchini M, Signore R, Testa I, Mazzanti L (1993) Effect of hydroxymethylglutaryl-CoA reductase inhibitors on the functional properties of erythrocyte membranes. Exp Mol Pathol 59(1):51-57
31. Ramanadham M, Kaplay SS (1982) Erythrocyte osmotic fragility in protein-energy malnutrition: cholesterol, phospholipid, and Ca2+, Mg2+ adenosine triphosphatase. Biochem Med 27: 226-231
32. Rose HG, Oklander M (1965) Improved procedure for the extraction of lipid from human erythrocytes. J Lipid Res 6:428-431
33. Rubenfire M, Maciejko JJ, Blevins RD, Orringer C, Kobylak L, Rosman H (1991) The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia. The Southeastern Michigan Collaborative Group. Arch Intern Med 151(11):2234-2240
34. Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, Yesil S (2005) The beneficial effects of lipidlowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia. Metabolism 54(5): 677-681
35. Stocks J, Dormandy TL (1971) The autoxidation of human red cell lipids induced by hydrogen peroxide. Br J Haematol 20:95-111
36. Thongtang N, Ai M, Otokozawa S, Himbergen TV, Asztalos BF, Nakajima K, Stein E, Jones PH, Schaefer EJ (2011) Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol 107(3):387-392
37. Tziakas DN, Chalikias GK, Stakos D, Tentes IK, Chatzikyriakou SV, Mitrousi K, Kortsaris AX, Boudoulas H, Kaski JC (2008) Cholesterol composition of erythrocyte membranes and its association with clinical presentation of coronary artery disease. Coron Artery Dis 19(8):583-590
38. Uyuklu M, Meiselman HJ, Baskurt OK (2007) Effect of decreased plasma cholesterol by atorvastatin treatment on erythrocyte mechanical properties. Clin Hemorheol Microcirc 36(1):25-33
39. Vayá A, Martínez Triguero M, Réganon E, Vila V, Martínez Sales V, Solá E, Hernández Mijares A, Ricart A (2008) Erythrocyte membrane composition in patients with primary hypercholesterolemia. Clin Hemorheol Microcirc 40(2):289-294
40. Yagi K (1994) Lipid peroxides and related radicals in clinical medicine. In: Free radicals in diagnostic medicine. Pleneum Press, New York, pp 1-15